The safety of switching between therapeutic proteins
Author:
Publisher
Informa Healthcare
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology
Link
http://www.tandfonline.com/doi/pdf/10.1517/14712598.2012.711308
Reference75 articles.
1. Biosimilars – Global issues, national solutions
2. Biosimilars—why terminology matters
3. Biosimilars of Biological Drug Therapies
4. Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council
5. Biosimilar agents in oncology/haematology: from approval to practice
Cited by 82 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Initial prescriptions and medication switches of biological products: an analysis of prescription pathways and determinants in the Swiss healthcare setting;BMJ Open;2023-11
2. No two classes of biosimilars: Urgent advice to the US Congress and the FDA;Journal of Clinical Pharmacy and Therapeutics;2022-07-22
3. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?;Drugs;2021-10-27
4. Therapeutic peptides for the treatment of cystic fibrosis: Challenges and perspectives;European Journal of Medicinal Chemistry;2021-03
5. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?;BioDrugs;2020-09-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3